Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 56

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 56
---
 third parties. We may be unable
to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business
operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would adversely
affect our business. We may need to cease use of, and may need to seek to develop alternative approaches that do not infringe on, such
intellectual property rights which may entail additional costs and development delays and such alternative approaches may not be feasible.
Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, and may allow
our competitors access to the same technologies licensed to us.

The patent positions of medical
device companies may involve complex legal and factual questions and have been the subject of much litigation in recent years, and therefore,
the scope, validity and enforceability of any patent claims that we have or may obtain cannot be predicted with certainty. Our pending
and future patent applications may not result in patents being issued in the United States or in other jurisdictions that protect our
technology or products or that effectively prevent others from commercializing competitive technologies and products. Changes in either
the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or
narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our products and inventions to the
same extent as the laws of the United States. While we enter into non-disclosure and confidentiality agreements with parties who have
access to confidential or patentable aspects of our research and development efforts, including for example, our employees, corporate
collaborators, external academic scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties,
any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby endangering our
ability to seek patent protection. In addition, publications of discoveries in the scientific and scholarly literature often lag behind
the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months
after filing, or in some cases not until issuance as a patent. Consequently, we cannot be certain that we were the first to file for patent
protection on the inventions claimed in our patents or pending patent applications. In addition, the USPTO might require that the term
of a patent issuing from a pending patent application be disclaimed and limited